• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Neurology

Carboplatin as a potential adjunct therapy for recurrent high-grade glioma treatment

byKathleen LauandAlex Chan
January 8, 2021
in Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

2 Minute Medicine Rewind June 13, 2022 

2 Minute Medicine Rewind June 6, 2022

2 Minute Medicine Rewind May 22nd, 2022

1. Carboplatin, given through intracerebral, convection-enhanced delivery, may be a viable adjunct in recurrent high-grade glioma treatment.

Evidence Rating Level: 1 (Excellent)

Patients with glioblastomas (GBM), which will invariably recur despite maximal therapy, have a poor prognosis, with a median overall survival of 15 months. The current treatment for newly diagnosed GBM includes surgical resection, concurrent radiation, and temozolomide with subsequent adjuvant temozolomide. Carboplatin is highly effective in treating other malignancies. However, while gliomas have been shown to be sensitive to this anti-cancer drug, using carboplatin has been limited by its systemic toxicity and its inability to penetrate the blood-brain barrier at effective concentrations. In this open-label, nonrandomized dose-escalation trial, 10 patients with recurrent WHO grade III or IV gliomas, who had previously undergone surgery and chemoradiation, were divided into cohorts of 3 patients each. They were treated with escalating doses of carboplatin at 1ug, 2ug, and 4ug in 54mL, delivered intracerebrally via convection enhanced delivery (CED) over 72 hours. No treatment-related deaths occurred, and no dose-limiting toxicities were observed. Neither were reported adverse events (total of 9) considered treatment-related, aside from one patient which experienced an isolated grade 2 generalized tonic-clonic seizure; this incident was resolved after halting carboplatin infusion (1.3ug dose) and the patient recovered to baseline medical status after infusion was halted within 24 hours. Progression-free survival at 6 months post-infusion was 20% (median 2.1 months) and 12-month overall survival was 40% (median 9.6 months). It is of note however, that the study’s inclusion and exclusion criteria led to a predominantly younger cohort (mean age= 46.8years) with high baseline KPS (Karnofsky performance score), may have contributed to the low incidence of adverse events and the trend towards more favourable survival. While this study shows intracerebral CED of carboplatin of up to 4ug is a safe and feasible adjunct to re-resection of recurrent GBMs, further research is needed with a larger sample size to determine maximum tolerated dose and the generalizability of these results.

Click to read the study in PLOSONE

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: glioblastomaneurology
Previous Post

#VisualAbstract: Low-dose capecitabine after standard adjuvant therapy improves disease-free survival in patients with early triple-negative breast cancer

Next Post

#VisualAbstract Fondazione Italiana Linfomi (FIL) Phase 3 trial: Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation (HSCT) in mantle cell lymphoma improves progression-free survival (PFS)

RelatedReports

Long-term outcomes for off-pump and on-pump CABG are similar
Weekly Rewinds

2 Minute Medicine Rewind June 13, 2022 

June 20, 2022
Weekly Rewinds

2 Minute Medicine Rewind June 6, 2022

June 6, 2022
Weekly Rewinds

2 Minute Medicine Rewind May 22nd, 2022

May 23, 2022
Stroke expansion following intra-arterial therapy may explain worse outcomes
Cardiology

Reduced bleeding risk with asundexian compared to apixaban in patients with atrial fibrillation

April 19, 2022
Next Post
#VisualAbstract Fondazione Italiana Linfomi (FIL) Phase 3 trial: Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation (HSCT) in mantle cell lymphoma improves progression-free survival (PFS)

#VisualAbstract Fondazione Italiana Linfomi (FIL) Phase 3 trial: Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation (HSCT) in mantle cell lymphoma improves progression-free survival (PFS)

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

2 Minute Medicine Rewind January 11, 2021

Lansoprazole not effective for the treatment of persistent throat symptoms

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Treatment of anal high-grade squamous intraepithelial lesions can reduce rates of progression to invasive anal cancer.
  • High tumour mutation burden in NSCLC associated with improved clinical outcomes of PD-L1 blockade across PD-L1 expression subgroups
  • Subsidization of supermarkets may help reduce obesity risk in children
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.